Stocktoria
Raphael Pharmaceutical Inc. RAPH
Raphael Pharmaceutical Inc. (RAPH) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 2036 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| RAPH | Raphael Pharmaceutical Inc. | 3/9 | — | — | — |
| TRLV | Trulieve Cannabis Corp. | 4/9 | 1.09 | — | -0.4% |
| USNA | USANA HEALTH SCIENCES INC | 6/9 | 7.37 | 32.6 | +8.3% |
| TLRY | Tilray Brands, Inc. | 2/9 | -3.61 | — | +11.5% |
| CRLBF | Cresco Labs Inc. | 3/9 | -2.99 | — | -9.5% |
| AAWH | Ascend Wellness Holdings, Inc. | 4/9 | -1.32 | — | -10.9% |
| CGC | Canopy Growth Corp | 4/9 | — | — | +10.5% |
About Raphael Pharmaceutical Inc.
Raphael Pharmaceutical Inc., a pharmaceutical drug research and development company, focuses on the discovery and clinical development of life-improving drug therapies based on cannabinoids. The company develops lead product candidate for the treatment of rheumatoid arthritis. It also intends to develop cannabinoid-based drug products for the treatment of oncology indications and other autoimmune diseases. Raphael Pharmaceutical Inc., is headquartered in Jaffa, Israel.
FAQ
Is RAPH financially healthy?
Raphael Pharmaceutical Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does RAPH pay a dividend?
No, Raphael Pharmaceutical Inc. does not currently pay a dividend.
Is RAPH overvalued or undervalued?
Raphael Pharmaceutical Inc. trades at about 20.0× trailing earnings — above its 10-year norm (10-year range 4.8×–20.0×, median 12.5×). Stocktoria reports the data, not buy/sell advice.
Is RAPH a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Raphael Pharmaceutical Inc.: a Piotroski F-score of 3/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.